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Summary
 
The efficacy of thalidomide (
 
a
 
-phthalimido-glutarimide) therapy in leprosy patients with
erythema nodosum leprosum is thought to be due to inhibition of tumor necrosis factor 
 
a
 
. In
other diseases reported to respond to thalidomide, the mechanism of action of the drug is un-
clear. We show that thalidomide is a potent costimulator of primary human T cells in vitro,
synergizing with stimulation via the T cell receptor complex to increase interleukin 2–medi-
ated T cell proliferation and interferon 
 
g
 
 production. The costimulatory effect is greater on the
CD8
 
1
 
 than the CD4
 
1
 
 T cell subset. The drug also increases the primary CD8
 
1
 
 cytotoxic T
cell response induced by allogeneic dendritic cells in the absence of CD4
 
1
 
 T cells. Therefore,
human T cell costimulation can be achieved pharmacologically with thalidomide, and prefer-
entially in the CD8
 
1
 
 T cell subset.
Key words: thalidomide • costimulation • T cells • CD8
 
1 
 
• pharmacologic immune 
modulation
 
T
 
halidomide’s immune-modulating effects were discov-
ered serendipitously over 30 years ago. Administration
of the drug, when prescribed as a sedative (its original indi-
cation) to leprosy patients with erythema nodosum lepro-
sum (ENL),
 
1
 
 was found to heal the inflammatory skin le-
sions and eliminate the systemic symptoms that characterize
that condition (1). We showed subsequently that the effi-
cacy of thalidomide in ENL is associated with a rapid re-
duction in the circulating level of the proinflammatory cy-
tokine TNF-
 
a
 
 (2). In further studies, we demonstrated that
thalidomide exerts a specific inhibitory effect on the pro-
duction of TNF-
 
a
 
 by lipopolysaccharide-stimulated mono-
cytes in vitro (3). These results suggested that inhibition of
this cytokine is a possible mechanism for the antiinflamma-
tory effects of thalidomide therapy.
Recently, studies in animal models and human diseases
have been initiated to explore the potential application of
this agent in a range of inflammatory and immunologic dis-
orders. Compelling data have now accumulated confirming
the efficacy of thalidomide in ENL (4) and in aphthous ul-
ceration complicating HIV disease (5, 6). Other studies
have suggested a potential application in chronic GVHD
(7, 8). The observation that thalidomide appears to be ef-
fective in these conditions when conventional immuno-
suppressive therapy (usually with corticosteroids) has failed
continues to stimulate interest in identifying the possible
mechanism(s) of action of this controversial agent.
There has been much interest in the possibility that thalid-
omide might not only affect monocyte cytokine produc-
tion, but also influence the functions of T cells, since the
latter have central effector and regulatory roles in immune
responses. However, the results of investigations by several
different groups have revealed no clear or consistent effect
of thalidomide on primary T cell responses. Taken to-
gether, these observations have suggested either that any ef-
fect on T cell function is indirect, or that such an effect is
elusive in conventional T cell assays.
Recent studies have shown that optimal activation of T
cells requires the delivery of a second, costimulatory signal
in addition to antigenic stimulation via the TCR (9). Phys-
iologically, these costimulatory signals are effected by inter-
actions between molecules on the surface of specialized
APCs and their ligands on T cells. Thus, modifying T cell
costimulation may have a profound impact on the integrity
of the immune response. This is exemplified by the immu-
nosuppressive effect of specifically blocking the interaction
of one such ligand pair, B7 (on the APC) and CD28 (on
the T cell) (10). Therefore, it is important to consider such
accessory pathways when investigating T cell function.
 
1
 
Abbreviations used in this paper: 
 
DC, dendritic cell; ENL, erythema no-
dosum leprosum; ER, erythrocyte-rosetting; GAF, glutaraldehyde-fixed;
r-hu, recombinant human; SEA and SEB, staphylococcal enterotoxin A
and B.
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Thalidomide Costimulation of T Cells
 
We set out to examine the effects of thalidomide on pri-
mary human T cell responses in vitro. Initially, we were in-
terested in studying the effects of thalidomide on TNF-
 
a
 
production by these cells, but found no effect of the drug
on this response. Unexpectedly, when purified T cells were
stimulated by antibodies to CD3, a component of the
TCR complex, thalidomide provided an essential costimu-
latory signal for T cell proliferation and lymphokine pro-
duction. The costimulatory effect of thalidomide was more
pronounced in the CD8
 
1
 
 subset of T cells. This is the first
example of a pharmacologic agent used in the treatment of
human disease that acts as a costimulator for T cells. More-
over, thalidomide preferentially stimulates CD8
 
1
 
 T cells.
 
Materials and Methods
 
Preparation of Cells
 
PBMCs and T Cells.
 
PBMCs were isolated from the blood of
healthy volunteers by Ficoll density gradient separation. T lym-
phocytes were purified by rosetting with neuraminidase-treated
sheep erythrocytes and subsequent incubation of erythrocyte-
rosetting (ER
 
1
 
) cells on a nylon wool column. Nonadherent cells
were eluted from the column and were 
 
$
 
97% CD3 antigen–pos-
itive by flow cytometry (FACStar
 
Ò
 
; Becton Dickinson, San Jose,
CA). The latter population we refer to herein as “bulk” T cells.
Primary CD4
 
1
 
 and CD8
 
1
 
 T cells were purified from PBMCs
by positive selection with magnetic beads coated with mouse
anti–human CD4 and anti-CD8 antibodies, respectively (Dynal
A.S., Oslo, Norway), at a bead/cell ratio of 2–3:1. Positively se-
lected cells were then dissociated from the beads by incubation
with a second antibody competing for the antigen binding site on
the primary anti–human antibody (Detachabead; Dynal A.S.).
These cells were 
 
$
 
98% CD4
 
1
 
CD3
 
1
 
 or CD8
 
1
 
CD3
 
1
 
 by flow
cytometry.
 
APCs.
 
PBMCs were enriched for APCs in experiments with
staphylococcal enterotoxin superantigens or in one-way alloge-
neic reactions by depletion of ER
 
1
 
 populations. For the latter
experiments, these non-erythrocyte-rosetting (ER
 
2
 
) populations
were irradiated with 2,000 rads from a cesium source. In experi-
ments with staphylococcal superantigens, ER
 
2
 
 populations were
rendered costimulator-deficient by 0.05% glutaraldehyde fixation
for 30 s, followed by the addition of 0.2 M 
 
l
 
-lysine to stop the
reaction and four washes in PBS.
These cell cultures were set up in RPMI medium (GIBCO
BRL, Gaithersburg, MD) supplemented with 10% heat-inacti-
vated FCS and penicillin/streptomycin.
 
Dendritic Cells.
 
Dendritic cells (DCs) were derived from pe-
ripheral blood progenitors as described by Bender et al. (11). In
brief, ER
 
2
 
 cells were incubated for 7 d with recombinant human
(r-hu) IL-4 (Genzyme Corp., Cambridge, MA) and r-hu GM-
CSF (Immunex, Seattle, WA), each at 1,000 u/ml, followed by a
4-d incubation with macrophage-conditioned medium. At the
end of this period, the cells exhibited stellate morphology charac-
teristic of DCs, were CD83
 
1
 
, HLA-DR
 
1
 
, and CD14
 
2
 
 by flow
cytometry, and were highly efficient inducers of proliferation and
cytotoxicity in purified alloreactive T cells.
 
Target Cells for CTL Assays.
 
To obtain target cells for the
CTL 
 
51
 
Cr-release assays, polystyrene-adherent ER
 
2
 
 cells from
either the same donor as the DCs (allogeneic targets) or the same
donor as the T cells (autologous control targets) were cultured in
Teflon tissue culture dishes in RPMI containing 5% human se-
rum at 37
 
8
 
C until required for the CTL assay (up to 1 wk).
 
Thalidomide
 
Thalidomide (Celgene Corp., Warren, NJ) was dissolved in
DMSO to give a stock solution of 20 mg/ml, which was kept for
up to 1 wk. Before stimulation, T cells were preincubated for 1–2 h
at 37
 
8
 
C with thalidomide or DMSO (control) at the concentra-
tions indicated in Results. Cell cultures were treated daily with
the appropriate dilutions of thalidomide stock or DMSO.
 
T Cell Stimulation
 
Purified T cells were stimulated in three experimental systems:
 
Cross-linking of the TCR by Immobilized Monoclonal Mouse Anti–
human CD3.
 
The anti-CD3 antibody (Orthoclone OKT3; a
gift of Dr. Robert Zivin, OrthoBiotech Inc., Raritan, NJ) was
diluted in PBS and coated onto flat-bottomed polystyrene tissue
culture plates by overnight incubation at 4
 
8
 
C, at concentrations
indicated in Results. In some experiments, exogenous r-hu IL-2
(Chiron Corp., Emeryville, CA) was added at a final concentra-
tion of 10 U/ml. Thalidomide- or DMSO-treated T cells were
added to 96-well plates at 10
 
5
 
 cells per well for triplicate prolifer-
ation assays, and to 24-well plates at 10
 
6
 
 cells per ml for the mea-
surement of cytokine production in culture supernatant fluid. In
preliminary experiments, unsorted PBMCs were also stimulated
in this system. In cytokine blocking experiments, cultures were
treated with polyclonal rabbit anti–human IL-2 or polyclonal
sheep anti–human IL-4 antibodies (Endogen, Inc., Cambridge,
MA) at final concentrations of 40 and 10 
 
m
 
g/ml, respectively.
 
Presentation of the Superantigens Staphylococcal Enterotoxin A and B
by Costimulator-deficient APCs.
 
Glutaraldehyde-fixed (GAF) APCs
were coincubated with purified CD4
 
1
 
 or CD8
 
1
 
 T cells and
both staphylococcal enterotoxin A and B (SEA and SEB; Toxin
Technology, Inc., Sarasota, FL,) so that the final concentration of
each superantigen was 10 ng/ml and the APC/T cell ratio was 1:1.
Cultures were set up in triplicate in 96-well round-bottomed tis-
sue culture plates, with 10
 
5
 
 of each cell type per well.
 
Stimulation of T Cells by Allogeneic DCs.
 
DC/T cell cocultures
were set up in round-bottomed 96-well plates. T cells were puri-
fied CD4
 
1
 
, CD8
 
1
 
, or recombined CD4
 
1
 
 and CD8
 
1
 
 (ratio of
2:1), and were treated with thalidomide or DMSO as above. Each
well contained 10
 
5
 
 T cells in a final volume of 0.2 ml. The ratio of
DC to T cells was 1:30.
 
T Cell Proliferation Assays
 
T cell proliferative responses were assayed by measuring
[
 
3
 
H]thymidine (NEN Research Products, Boston, MA) incorpo-
ration during the last 12 h of 120-h cultures. DNA was harvested
onto fiber mats with an automatic cell harvester (Skatron Instru-
ments Inc., Sterling, VA), and [
 
3
 
H]thymidine incorporation was
measured with a betaplate liquid scintillation counter (model
LKB 1205; Wallac, Gaithersburg, MD).
 
CTL Assays
 
Standard 6-h 
 
51
 
Cr-release assays were set up as described by
Young and Steinman (12). On the day of assay, 5 
 
3
 
 10
 
3
 
 
 
51
 
Cr-
labeled monocytic target cells were added to the wells in the
96-well plates, and supernatants were collected with a multiwell
harvesting frame (Skatron Instruments Inc.) after a 6-h incuba-
tion. Released radioactivity was measured with an automated 
 
g
 
counter (Wallac). Identical 96-well plates set up in parallel were 
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pulsed with [
 
3
 
H]thymidine for 12 h to measure lymphocyte pro-
liferation. Assays were set up in triplicate for each experimental
condition. Spontaneous release in the absence of effector cells and
total release after detergent lysis of targets were also measured.
Specific lysis was calculated as (cpm
 
experimental
 
 
 
2
 
 cpm
 
spontaneous
 
) 
 
4
 
(cpm
 
total
 
 
 
2
 
 cpm
 
spontaneous
 
) 
 
3
 
 100%.
 
Cytokines
 
Tissue culture supernatants were harvested and frozen immedi-
ately at 
 
2
 
70
 
8
 
C until assay in duplicate for IL-2, IFN-
 
g
 
, IL-4, or
TNF-
 
a
 
 by enzyme-linked immunoassay (Endogen, Inc.).
 
Donor Blood and Experimental Design
 
Blood for these experiments was drawn from a total of nine
healthy adult donors. Each experiment was repeated at least three
times with different donors. The observations reported here were
consistently present in experiments from all donors. Findings
from individual representative experiments are shown to illustrate
each point.
 
Results
 
Effect of Thalidomide on T Cell Proliferative Responses after
Stimulation by Immobilized Anti-CD3.
 
Preliminary experi-
ments carried out on PBMCs obtained from two healthy
tuberculin-sensitive donors showed no effect of thalido-
mide on lymphocyte proliferative responses to the mito-
gens PHA and PMA, the superantigens SEA and SEB, or
purified protein derivative (data not shown). However,
when PBMCs from three individual donors were stimu-
lated by cross-linking the TCR with immobilized anti-
CD3 mAbs alone, thalidomide induced a concentration-
dependent increase in proliferative responses (Fig. 1).
In subsequent studies, the effect of thalidomide on puri-
fied peripheral blood T cells (“bulk” T cells) was evaluated.
Exposure to a constant concentration of thalidomide (10
 
m
 
g/ml) caused a marked enhancement of proliferative re-
sponses to increasing concentrations of anti-CD3 (Fig. 2
 
A
 
). At low concentrations of anti-CD3, the T cells failed to
respond unless thalidomide was added. This effect was also
evident in purified CD4
 
1
 
 and CD8
 
1
 
 T cell subsets (Fig. 2
 
B
 
). Again, there was no proliferative response to thalido-
mide in the absence of anti-CD3, indicating that thalido-
mide was not mitogenic per se, but acted as a costimulator.
We observed that significant augmentation of the prolifera-
tive response by thalidomide occurred at lower concentra-
tions of anti-CD3 for bulk and CD8
 
1
 
 T cells than for
CD4
 
1
 
 T cells (Fig. 2, 
 
A
 
 and 
 
B
 
). Fig. 2 
 
C
 
 shows that when
the concentration of anti-CD3 was constant, there was a
thalidomide concentration–dependent increase in prolifera-
tive responses in all three lymphocyte populations. This ef-
fect was relatively modest in the CD4
 
1
 
 T cell subset com-
pared with bulk or CD8
 
1
 
 T cells within individual
donors, although large thalidomide-induced increases in
the CD4
 
1
 
 T cell response were seen in some individuals.
To confirm that the differential effect of thalidomide on
the two T cell subsets was not due to an incapacity of the
CD4
 
1
 
 population to respond fully, experiments were car-
ried out using PMA, a well-described chemical costimula-
tor of T cells. Addition of PMA stimulated CD4
 
1
 
 and
CD8
 
1
 
 T cell proliferation similarly, in contrast to thalido-
mide (data not shown).
In further experiments, when the TCR was cross-linked
by anti-CD3 in the presence of exogenous 
 
r
 
IL-2 (10 U/ml),
no effect of thalidomide on T cell proliferation was appar-
ent (Fig. 2 
 
D
 
). However, when the cytokine was not
added, thalidomide substituted almost completely for exog-
enous IL-2 in stimulating the proliferative responses of
CD8
 
1
 
 T cells, while restoring 
 
z
 
50% of the CD4
 
1
 
 T cell
response under the same conditions (Fig. 2 
 
D).
Effect of Thalidomide on T Cell Production of Cytokines.
We next examined the effect of thalidomide on cytokine
production by the three T cell populations when stimu-
lated by anti-CD3 in the absence of exogenous IL-2. Tha-
lidomide induced a consistent concentration-dependent in-
crease in IL-2 production at 12 h (time of peak production
determined in preliminary kinetic experiments), in CD81
and in bulk T cells (Fig. 3 A). Although a trend towards a
thalidomide dose response in IL-2 production by purified
CD41 T cells was apparent, production of this cytokine
was modest in comparison to that of bulk and CD81 pop-
ulations. Exposure to thalidomide consistently increased
IFN-g production by all three T cell populations. Since
there was no clear peak in production of the latter cyto-
kine, the results of a kinetic experiment are shown for
CD41 and CD81 T cells (Fig. 3 B) using a single concen-
tration of thalidomide (10 mg/ml). Again, the drug induced
relatively greater production of IFN-g by purified CD81
T cells. However, the thalidomide-induced augmentation
of IFN-g production by CD41 T cells was marked in
comparison to the drug’s weak effect on IL-2 production
Figure 1. Effect of thalidomide on mean proliferative responses of
PBMCs from three healthy donors stimulated with 10 mg/ml immobi-
lized anti-CD3. PBMCs (105/well) were cultured in triplicate at the indi-
cated concentrations of thalidomide. [3H]Thymidine incorporation was
measured for the last 12 h of 120-h cultures. Results are expressed as
mean6SD. 100% activity on the y axis represents [3H]thymidine incorpo-
ration in the absence of thalidomide (DMSO-treated control).1888 Thalidomide Costimulation of T Cells
by this subset. Bulk T cells displayed a similar IFN-g pro-
file to CD81 T cells (data not shown). All three lympho-
cyte populations showed a concentration-dependent in-
crease in IFN-g production in response to thalidomide
(data not shown). In contrast, thalidomide did not affect
significantly the production of TNF-a by either bulk or
CD81 T cells, and the production of TNF-a by CD41
cells was minimal in this system (Fig. 3 C). A critical conse-
quence of T cell costimulation is the production of IL-2.
Thus, experiments to evaluate the effect of the drug on
TNF-a production were also carried out in which exoge-
nous IL-2 was added to eliminate the costimulatory effect
Figure 2. (A) Effect of thalidomide (10 mg/ml) on
the proliferative response of purified (.97% CD31) T
cells in the presence of increasing concentrations of im-
mobilized anti-CD3. Filled symbols, Thalidomide-
treated cultures. Open symbols, DMSO-treated controls.
(B) Effect of thalidomide (10 mg/ml) on the prolifera-
tive response of highly purified positively selected
CD41 (squares) and CD81 (circles) T cell subsets in the
presence of increasing concentrations of immobilized
anti-CD3.  Filled symbols, Thalidomide-treated cells.
Open symbols, DMSO-treated controls. (C) Effect of
thalidomide on proliferation of purified bulk T cells (di-
amonds), CD41 (squares), and CD81 (circles) subsets in
the presence of anti-CD3 at 0.1 mg/ml for bulk and
CD81, 10 mg/ml for CD41 T cells. Symbols on the y
axis represent responses in the absence of thalidomide
(DMSO-treated control). T cells (105/well) were cul-
tured in triplicate at the indicated concentrations of
anti-CD3. [3H]Thymidine incorporation was measured
for the last 12 h of 120-h cultures. (D) Lack of effect of
thalidomide (Thal; 50 mg/ml) on CD41 and CD81 T
cell proliferative responses to immobilized anti-CD3
(10  mg/ml) in the presence of exogenous r-hu IL-2 (10
U/ml). In the absence of exogenous IL-2, the enhance-
ment by thalidomide of proliferation of CD81 T cells
is equivalent to that observed when exogenous IL-2 is
present. Data expressed as percent activity of anti-CD3
plus IL-2–induced [3H]thymidine incorporation. T
cells (105/well) were cultured in triplicate, and [3H]thy-
midine incorporation was measured for the last 12 h of
120-h cultures.
Figure 3. (A) Effect of thalidomide on IL-2 produc-
tion by T cells stimulated with immobilized anti-CD3
(12 h). Diamonds, Bulk T cells. Squares, CD41 T cells.
Circles, CD81 T cells. (B) Effect of thalidomide (10
mg/ml) on the kinetics of IFN-g production by
CD41 (squares) and CD81 (circles) T cells stimulated
with immobilized anti-CD3. Filled symbols, Thalidomide-
treated cells. Open symbols, DMSO-treated controls.
(C) Lack of effect of thalidomide on TNF-a produc-
tion by T cells stimulated with immobilized anti-CD3
(12 h). Symbols as in A. Cytokine concentrations were
determined by ELISA of culture supernatants. No IL-4
was detected. (D) Effect of polyclonal rabbit anti–
human IL-2 (anti-IL-2; 40 mg/ml) and polyclonal
sheep anti–human IL-4 (anti-IL-4; 10 mg/ml) on thalid-
omide (Thal)-induced proliferation of bulk (white bars),
CD41 (gray bars), and CD81 (hatched bars) T cells.
Results for appropriate control antibodies (Rab Ctl IgG
and Shp Ctl IgG) at the same concentrations are also
shown. [3H]Thymidine incorporation was measured
for the last 12 h of 120-h triplicate cultures.1889 Haslett et al.
of thalidomide. Again, no consistent inhibitory effect of
thalidomide on TNF-a production by T cells was found
(data not shown). IL-4 was not detected in the supernatants
of T cells stimulated with anti-CD3 in the presence or ab-
sence of thalidomide (data not shown).
Taken together, these observations suggested that thalid-
omide-induced T cell proliferation was dependent on the
autocrine production of IL-2 but not IL-4. To confirm
these findings, neutralization of IL-2 by a polyclonal anti-
body was carried out. Anti–IL-2 abrogated the proliferative
effect of thalidomide, whereas the addition of anti–IL-4 an-
tibody had no effect. This observation was consistent in the
three T cell populations under study (Fig. 3 D), and con-
firmed that the stimulatory effect of thalidomide was de-
pendent on the induction of endogenous IL-2 production.
Together, these experiments suggest that thalidomide is
acting as a costimulus to T cells, which have received a pri-
mary signal through the cross-linked TCR.
Effect of Thalidomide on Lymphocyte Proliferative Responses to
Staphylococcal Superantigens Presented by Autologous GAF
APCs. Next, we sought to determine whether thalido-
mide could costimulate T cell responses after superantigen
presentation by APCs. PBMCs enriched for APCs were
fixed in 0.05% glutaraldehyde. This chemical modification
rendered the APCs deficient in costimulatory function (13,
14) while preserving their capacity to present staphylococ-
cal superantigens to purified autologous CD41 and CD81
T cells. When T cells were exposed to thalidomide in this
system, there was a marked increase in CD41 and CD81
T cell proliferative responses (Fig. 4). The absolute re-
sponse of CD81 T cells was modest in comparison with
that of CD41 T cells, since characteristically, CD41 T
cells respond more vigorously to superantigens. However,
the fold increase in response to thalidomide relative to cells
treated with DMSO was consistently greater in CD81
than in CD41 T cells if expressed as a “stimulation ratio”
(thalidomide cpm 4 DMSO cpm). Accordingly, the mean
(6SD) stimulation ratio was 7.14 (63.55) for CD81 T
cells in three experiments versus 3.88 (61.04) for CD41 T
cells in six experiments.
Effect of Thalidomide on the Proliferative and Cytotoxic Re-
sponses of Purified CD81 T Cells in a DC/T Cell Primary Al-
logeneic Reaction. To evaluate the effect of thalidomide on
T cells receiving a more physiologic stimulus, we set up
cocultures of purified T cells with blood-derived HLA-
mismatched DCs and studied primary CTL killing of allo-
geneic targets. A standard 6-h microassay was used. Mono-
cytes (from the same donor as the DCs) labeled with 51Cr
were used as targets. No significant cytotoxic activity was
observed before day 4 of DC/T cell coculture. Maximum
CTL activity by purified CD81 T cells was observed on
days 4–5 (Fig. 5 D), whereas recombined CD41 and
CD81 T cells showed peak CTL activity on days 5–6 (Fig.
5  F). Purified CD41 T cells stimulated with allogeneic
DCs were not cytotoxic (Fig. 5 E). Thalidomide increased
both proliferative and cytotoxic responses of purified CD81
T cells in the absence of CD41 T cells (Fig. 5, A and D).
However, when a mixed CD41/CD81 T cell population
was reconstituted at a physiologic ratio of 2:1, no signifi-
cant enhancing effect of thalidomide was evident (Fig. 5, C
and F). Similarly, thalidomide did not enhance the prolifer-
ative response of a purified CD41 T cell population (Fig. 5
B). Thus, CD81 T cell functional responses to allogeneic
DCs can be further enhanced by thalidomide, but only in
the absence of CD41 T cell “help.”
Discussion
Several different immunomodulating and/or antiinflam-
matory mechanisms of action have been suggested for tha-
lidomide, including the specific inhibition of TNF-a both
in vitro and in vivo (2, 3, 15). In addition, in vitro investi-
gations have shown that thalidomide can modify surface
adhesion molecules on leucocytes (16), cause a shift from
Th1 to Th2 type T cell responses (17), and inhibit produc-
tion of monocyte IL-12 (18), as well as inhibit angiogenesis
(in an animal model of corneal neovascularization [19]).
Reports of thalidomide’s efficacy in GVHD in animal
models (20–22) and in clinical studies (7, 8) suggested that
the drug might modify T cell responses. However, several
investigations seeking to demonstrate an inhibitory action
of thalidomide on T cell responses have resulted in incon-
sistent findings (23–25).
In this study, we report that thalidomide can consistently
boost primary human T cell responses in vitro by acting as
a costimulatory molecule. The optimal demonstration of
this effect required that the T cells be highly purified, and
that a single stimulus be delivered to the T cell via the
TCR. Experiments with sorted cells revealed that for every
Figure 4. Effect of thalidomide (Thal; 50 mg/ml) on CD41 (gray bars)
and CD81 (hatched bars) T cell proliferative responses to SEA and SEB
(combined, SAg: 10 ng/ml each) presented by autologous GAF ER2
cells. Cultures were set up in triplicate in 96-well U-bottomed plates,
with 105 T cells/well. ER2/T cell ratio was 1:1. [3H]Thymidine incor-
poration was measured for the last 12 h of 120-h cultures.1890 Thalidomide Costimulation of T Cells
donor, the relative response to thalidomide was more pro-
nounced in the CD81 than the CD41 T cell subset, al-
though substantial costimulation of CD41 T cells was ob-
served occasionally. This differential effect contrasted with
the effect of PMA, a reagent used in vitro to costimulate T
cells, which exerted a similar effect on both CD41 and
CD81 T cells. Pharmacokinetic data indicate that the co-
stimulatory effects of thalidomide could be achieved at
concentrations as low as the 1–2 mg/ml attained in the
plasma of human subjects after thalidomide treatment (26).
In contrast to systems in which we tested for costimula-
tion of T cells stimulated with anti-CD3, no effect of the
drug on proliferative responses was seen when unsorted
PBMCs were stimulated by recall antigens or mitogens.
Therefore, the costimulatory effect of thalidomide is apt to
be overlooked in in vitro systems where the dominant re-
sponse is by CD41 T cells, and in experiments designed to
reveal inhibition rather than stimulation. Interestingly, two
recent studies showed a stimulatory effect of thalidomide
(27) and thalidomide metabolites (28) on IL-2 production
by mitogen-stimulated PBMCs, but found no effect on T
cell proliferation.
The differential costimulatory effect of thalidomide on
CD81 T cell proliferation is intriguing. To examine the
effect of thalidomide on a well-characterized functional
CD81 response in a more physiologically relevant system,
we induced primary cytotoxic T cell responses by stimula-
tion with allogeneic DCs. The latter experiments con-
firmed the differential effect of thalidomide in stimulating
proliferative responses in CD81 but not CD41 T cells,
and in increasing CD81 CTL responses. Moreover, the
costimulatory effect on CD81 T cells was not observed in
the presence of CD41 T cells, suggesting that in the pres-
ence of physiologic CD41 T cells, no further help is re-
quired, and that the effects of thalidomide on CD81 T
cells are superfluous. Similarly, any costimulatory effect of
the drug on CD41 T cells is inapparent in the presence of
a full complement of physiologic costimulatory signals, as
delivered by DCs. Thus, the costimulatory effects of tha-
lidomide on CD81 T cell function may have particular
relevance in clinical settings where CD41 T cell function
is defective, such as in HIV disease, or in situations where
there is a defect in T cell costimulation.
These in vitro observations of differential costimulation
of T cells by thalidomide may have an in vivo counterpart.
We reported recently a differential increase in circulating
CD81 over CD41 T cell numbers in 13 patients with
HIV infection treated with thalidomide, resulting in a drop
in the CD41/CD81 ratio (29). A consistent drug-induced
increase in plasma levels of soluble IL-2 receptor, a marker
of T cell activation, was also seen in this cohort. Further-
more, we have observed the restoration of delayed-type
cutaneous hypersensitivity to purified protein derivative of
tuberculin during thalidomide treatment in five previously
anergic patients with HIV infection (reference 15, and our
unpublished findings), which was lost after stopping the
drug. These findings are consistent with T cell stimulation
by thalidomide in patients in vivo, and raise the interesting
possibility that this agent may have a novel application as an
immunologic adjuvant in HIV disease.
Although thalidomide is the drug of choice in ENL (4),
corticosteroids are often used in the management of this
condition when thalidomide is unavailable. A recent con-
trolled trial has established the efficacy of thalidomide in
the treatment of refractory HIV-associated oral aphthous
ulceration (5). This agent has also been used in the man-
agement of chronic GVHD when alternatives, notably cor-
ticosteroids, have failed. The ability of thalidomide to act in
Figure 5. Effect of thalidomide on prolifera-
tive (top) and cytotoxic (bottom) T cell responses
to allogeneic stimulation by blood-derived DCs.
DC/T cell cocultures were set up at a ratio of 1:
30 for the durations indicated. Triplicate cul-
tures of 105 purified CD81 (A and D), CD41
(B and E), and recombined CD41/CD81 (ra-
tio 2:1; C and F) T cells were set up on day 0.
For proliferation assays, 1 mCi [3H]thymidine
was added for the last 12 h of culture. For cyto-
toxicity assays, 5 3 103 51Cr-labeled allogeneic
monocytes (from the same donor as the DCs)
were added to the cultures on the day of assay,
and 51Cr release over 6 h was measured. Sponta-
neous release of 51Cr was ,25% of the total.
There was no detectable cytotoxicity against au-
tologous (control) targets. Filled symbols, Thalid-
omide-treated cultures. Open symbols, DMSO-
treated controls.1891 Haslett et al.
lieu of such immunosuppressive agents has contributed to a
perception that thalidomide is also an immunosuppressive
drug (17, 23). However, on a clinical level, the classical in-
fectious complications of standard immunosuppressive thera-
pies (glucocorticoids and cyclosporin A) have never been
reported with thalidomide treatment, arguing powerfully
against indiscriminate suppression of immunity by this agent.
Together with these observations, our data suggest that im-
mune modulation by thalidomide may occur through the
inhibition of TNF-a production and/or the promotion of
T cell responses, without inhibiting normal immunity.
We suggest that the differential CD81 T cell stimulating
effects of thalidomide may contribute to the clinical im-
mune-modulating effects of the drug, including its antiin-
flammatory properties. Indeed, it has been demonstrated
that CD81 T cells can regulate immune responses by a va-
riety of mechanisms (30–32). Inflammatory bowel disease
represents one clinical setting where there is evidence that
the immunopathology may be due in part to a failure of ac-
tive immune regulation by mucosal CD81 T lymphocytes
(33, 34). Therefore, it is interesting in the context of the
findings presented here to note anecdotal reports of the ef-
ficacy of thalidomide in treating refractory inflammatory
bowel disease (35, 36). However, inhibition of TNF-a by
thalidomide may also play an important role in this setting
(37). These considerations suggest that inflammatory bowel
disease might be an appropriate clinical scenario in which
to explore the clinical correlates of our in vitro findings.
In conclusion, we have shown a novel and unique prop-
erty of thalidomide in differentially costimulating CD81 T
cells. Further clinical and laboratory-based studies are nec-
essary to test the hypothesis that the costimulatory or adju-
vant effects of thalidomide treatment on T cell responses
contribute to its efficacy in a wide range of clinical disorders.
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